{"ticker": {"uuid": "822d7872-e584-4d09-917b-78dbda387788", "symbol": "TNXP", "name": "Tonix Pharmaceuticals Holding Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Total debt per share of Tonix Pharmaceuticals Holding Corp. \u2013 GETTEX:TPM0", "summary": "The article focuses on the \"Total debt per share\" of Tonix Pharmaceuticals Holding Corp. (GETTEX:TPM0) as listed on TradingView. It appears to be a financial data page rather than a detailed news article. The content provides navigational links and information about TradingView's", "url": "https://www.tradingview.com/symbols/GETTEX-TPM0/financials-statistics-and-ratios/total-debt-per-share/", "source_name": "TradingView", "published_at": "2026-07-21T04:10:42", "published_display": "21 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals (TNXP) Investor presentation Summary", "summary": "Tonix Pharmaceuticals has launched Tonmya, a sublingual tablet for fibromyalgia, which has achieved $5.1 million in net sales and secured broad commercial and government insurance coverage. The company has a strong cash position of $185.5 million and an extensive pipeline of drug", "url": "https://quartr.com/events/tonix-pharmaceuticals-holding-corp-tnxp-investor-presentation_FPasHadc", "source_name": "Quartr", "published_at": "2026-07-18T01:11:21", "published_display": "18 Jul 2026 01:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models", "summary": "Tonix Pharmaceuticals announced the publication of a study in the Journal of Virology that assesses the virulence of the 2022 mpox outbreak strain (clade IIb) compared to the 2003 strain (clade IIa) using new murine models. The research found that the clade IIb strain is 100 to 1", "url": "https://finance.yahoo.com/healthcare/articles/tonix-pharmaceuticals-announces-publication-peer-130500762.html", "source_name": "Market source", "published_at": "2026-07-16T01:11:22", "published_display": "16 Jul 2026 01:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Paper Introduces Three New Mouse Models for Mpox Vaccine Research", "summary": "Tonix Pharmaceuticals announced that the Journal of Virology published its research on new mpox animal models, revealing that the 2022 clade IIb strain is 100 to 100,000-fold less virulent than the 2003 clade IIa strain. The study expands existing mouse models and introduces thre", "url": "https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-publication-in-the-peer-reviewed-qgbzdklcjmm8.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:46:59", "published_display": "15 Jul 2026 12:46", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Tonix Pharmaceuticals Holding Corp. (TNXP) Risk Zones", "summary": "This article analyzes Tonix Pharmaceuticals Holding Corp. (TNXP), highlighting a mid-channel oscillation pattern and a weak long-term outlook despite positive sentiment. It details distinct AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with specifi", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Tonix_Pharmaceuticals_Holding_Corp._TNXP_Risk_Zones_071426123801_1784003881.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-14T23:46:59", "published_display": "14 Jul 2026 23:46", "sentiment": "negative", "sentiment_pct": 30, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Announces Major Medicare Coverage Agreement for TONMYA, Expanding U.S. Access to Approximately 145 Million Covered Lives", "summary": "Tonix Pharmaceuticals announced a major managed Medicare agreement for TONMYA, adding approximately 9 million Medicare lives starting January 1, 2027, and bringing total covered lives to 145 million. The company is also expanding its sales force by 50 representatives to enhance a", "url": "https://www.quiverquant.com/news/Tonix+Pharmaceuticals+Announces+Major+Medicare+Coverage+Agreement+for+TONMYA,+Expanding+U.S.+Access+to+Approximately+145+Million+Covered+Lives", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T11:13:00", "published_display": "14 Jul 2026 11:13", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP)", "summary": "", "url": "https://finance.yahoo.com/m/b981db40-07b6-31b0-9d13-ad50a7f14be4/tonix-expands-tonmya-medicare.html", "source_name": "InvestorsHub", "published_at": "2026-07-13T12:21:44+00:00", "published_display": "13 Jul 2026 12:21", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tonix-pharmaceuticals-reaches-medicare-coverage-120031738.html", "source_name": "MT Newswires", "published_at": "2026-07-13T12:00:31+00:00", "published_display": "13 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA\u00ae", "summary": "Tonix Pharmaceuticals announced a new agreement for TONMYA (cyclobenzaprine HCl sublingual tablets) with a major managed Medicare payer, effective January 1, 2027, adding approximately 9 million Medicare lives. This expands TONMYA's coverage to about 46% of all covered lives in t", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326064/0/en/Tonix-Pharmaceuticals-Announces-Major-Managed-Medicare-Payer-Agreement-for-TONMYA.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T11:40:06", "published_display": "13 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Adds Medicare Part D Coverage for TONMYA, Expands Sales Force", "summary": "Tonix Pharmaceuticals announced a PBM agreement to secure Medicare Part D coverage for TONMYA, effective January 1, 2027, significantly expanding patient access to approximately 9 million beneficiaries. This new coverage, combined with existing Medicaid and commercial agreements,", "url": "https://www.tradingview.com/news/tradingview:3021d492c14dc:0", "source_name": "TradingView", "published_at": "2026-07-13T11:11:22", "published_display": "13 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals (NASDAQ: TNXP) secures PBM Medicare pact, targeting 145M TONMYA covered lives", "summary": "Tonix Pharmaceuticals has secured an agreement with a pharmacy benefit manager for TONMYA coverage for Medicare Part D beneficiaries, effective January 1, 2027, adding approximately 9 million Medicare lives. This new agreement, combined with existing commercial and Medicaid cover", "url": "https://www.stocktitan.net/sec-filings/TNXP/8-k-tonix-pharmaceuticals-holding-corp-reports-material-event-ad2ff3f89944.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:11:22", "published_display": "13 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fibromyalgia drug TONMYA to reach 145M covered lives by 2027", "summary": "Tonix Pharmaceuticals announced a major managed Medicare agreement for its fibromyalgia drug, TONMYA, adding approximately 9 million Medicare lives, bringing the total projected pharmacy coverage to 145 million covered lives by January 1, 2027. This expansion, combined with exist", "url": "https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-major-managed-medicare-payer-2zlnl3uf4paw.html", "source_name": "Stock Titan", "published_at": "2026-07-13T10:59:33", "published_display": "13 Jul 2026 10:59", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form 4 Tonix Pharmaceuticals Holding Corp For: 9 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Tonix Pharmaceuticals Holding Corp. on July 9, 2026. The brief entry provides the company's stock symbol (TNXP) and notes a 1.96% increase, indicating recent activity in the company's stock.", "url": "https://ng.investing.com/news/stock-market-news/form-4-tonix-pharmaceuticals-holding-corp-for-9-july-93CH-2593304", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T14:41:24", "published_display": "09 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix (NASDAQ: TNXP) CFO adds 1,453 shares through 2025 employee stock plan", "summary": "Tonix Pharmaceuticals Holding Corp.'s CFO, Bradley Saenger, acquired 1,453 shares of common stock at $10.914 per share through the company's 2025 Employee Stock Purchase Plan. This transaction, coded as \"J\" for \"other acquisition or disposition,\" is compensation-related and not a", "url": "https://www.stocktitan.net/sec-filings/TNXP/form-4-tonix-pharmaceuticals-holding-corp-insider-trading-activity-05e9cbc53d03.html", "source_name": "Stock Titan", "published_at": "2026-07-09T12:51:43", "published_display": "09 Jul 2026 12:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to TNXP Trends in Macro Strategies", "summary": "The article provides a technical analysis of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) with insights into near, mid-term, and long-term trends. It highlights a strong sentiment in the near and mid-term, but a weak long-term outlook, identifying an exceptional risk-reward", "url": "https://news.stocktradersdaily.com/news_release/35/Technical_Reactions_to_TNXP_Trends_in_Macro_Strategies_070226113001_1783049401.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T23:30:00", "published_display": "02 Jul 2026 23:30", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Announces First Patient Enrolled in", "summary": "Tonix Pharmaceuticals announced the enrollment of the first patient in its Phase 2 HORIZON study for TNX-102 SL, a treatment for Major Depressive Disorder (MDD). The study evaluates TNX-102 SL 5.6 mg as a first-line monotherapy, targeting disturbed sleep quality in MDD patients. ", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318861/0/en/tonix-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-horizon-study-of-tnx-102-sl-for-the-treatment-of-major-depressive-disorder-mdd.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T20:40:44", "published_display": "29 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 \u201cHORIZON\u201d study of TNX-102 SL (sublingual tablet) for the treatment of major depressive disorder (MDD).", "summary": "Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 \"HORIZON\" study for TNX-102 SL, a sublingual tablet designed to treat major depressive disorder (MDD). This milestone, reported to the SEC, marks significant progress in the clinical development of ", "url": "https://www.bitget.com/amp/news/detail/12560605481850", "source_name": "Bitget", "published_at": "2026-06-29T20:11:43", "published_display": "29 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals (TNXP) enrolls first patient in Phase 2 HORIZON MDD trial", "summary": "Tonix Pharmaceuticals has announced the enrollment of the first patient in its Phase 2 HORIZON trial for TNX-102 SL 5.6 mg as a first-line monotherapy for adults with major depressive disorder (MDD). This 6-week, randomized, double-blind, placebo-controlled study plans to enroll ", "url": "https://www.stocktitan.net/sec-filings/TNXP/8-k-tonix-pharmaceuticals-holding-corp-reports-material-event-121c965a72d3.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:10:33", "published_display": "29 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix enrolls first patient in Phase 2 depression study", "summary": "Tonix Pharmaceuticals has enrolled the first patient in its Phase 2 HORIZON study for major depressive disorder. The trial will involve approximately 360 patients across 30 U.S. sites and will assess TNX-102 SL (TONMYA), which is already FDA-approved for fibromyalgia, as a first-", "url": "https://grafa.com/en/news/united-states/tonix-horizon-depression-phase2-first-patient", "source_name": "grafa.com", "published_at": "2026-06-29T16:03:00", "published_display": "29 Jun 2026 16:03", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tonix-pharmaceuticals-advances-tnx-102-121519915.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:15:19+00:00", "published_display": "29 Jun 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for Major Depressive Disorder", "summary": "Tonix Pharmaceuticals has announced the enrollment of the first patient in its Phase 2 HORIZON study for TNX-102 SL, investigating its use as a first-line treatment for major depressive disorder (MDD). The study aims to enroll approximately 360 participants to evaluate changes in", "url": "https://www.quiverquant.com/news/Tonix+Pharmaceuticals+Announces+First+Patient+Enrolled+in+Phase+2+HORIZON+Study+of+TNX-102+SL+for+Major+Depressive+Disorder", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T11:30:00", "published_display": "29 Jun 2026 11:30", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)", "summary": "Tonix Pharmaceuticals has enrolled the first patient in its Phase 2 HORIZON study for TNX-102 SL in treating major depressive disorder (MDD). The 6-week, randomized, double-blind, placebo-controlled trial aims to enroll approximately 360 adults and will evaluate the drug as a fir", "url": "https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-fmo8cidv858m.html", "source_name": "Stock Titan", "published_at": "2026-06-29T11:11:57", "published_display": "29 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating (NASDAQ:TNXP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNV2RRcGpfOGRCZnFOLWRzSHVEQW8ySzU3QjQwZ096bm9iZUFXZEJVRF94RGdQYktNYUo0ZUpvLTJ4V0hyR0xxNm5tRWExR1dUTGNPaWlsN0p5Wk9KNU44TkFsOFBDa3YyZEVPb1drTUY4Z19hQ1dGV0ZTZjVwZEJMUklIdE5tOHdJUGV1Z25aY3VjcWoyamllb2hhV3QwbmZmbmlIVmlqT3hhbzBmaUdv?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/raymond-james-initiates-coverage-tonix-113700673.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:37:00+00:00", "published_display": "25 Jun 2026 11:37", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium group reports 890,366 shares (5.6%) in Tonix (TNXP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQZnRYM1J2R0l3aUpoQVlScVhXX0JPTHJfWDdwUC05TU1LbFhzS2pmLXJYOUM0RHpISkNrZzhwZFdLVHktaUo2VXdWbDB6U1prMXFhMjJpREdoeXcwbVpMay1iSVllVnpoRjJNQ3cxNENlcG1FR25SeGpTdkxEX2haV0R3ZUxEM0FhdXZicC12VHNxNnZJTzlWa1BZSDJ2WG1FM3JicGItZ1RSQlpocnhHdlI2QzRlX0ZTdTlaX0pRSHpMUjk5TlptdHE3OA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Carolyn Taylor buys Tonix Pharmaceuticals (TNXP) shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPLVBfNDZudGYzWEdHcnF5Qnlna3o3RnlnWlF4X2JnYVFhUWVJbzFkd3Fqc3RldDdnUHZub0ZaaTRPTHUycS0zSENvNEtra19NM1hKaHJDUy0tWjBKVHFTQ3JGQXpQZFNKaFJEdnlGblQzUmo1QkNuV01jT3VCQ19YajF1bnBldU85ZmJ2X1NDcm5PVEhibXRLaEN4RlRsT29wN3E3V25rR2t5RWFnNFFyLWxMZG1feUVObzdfRVpkYlB1bUlmaFJv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOVkRoYUF1U0tkbXEzYzF2VElfLTcweEtWRzZPUGpFbUJiWUhncHRkd3F1bWJPSTFCdG1FSVVzZGh3OUsxX1BkazU0dGRwNVNvaWRiazFHWndwUDRjeDY4N3BhT2FmM3F2VjhFcGI5VF9LMUh3MDJJQmU0a2xST2YtTzdUVXRlOXJXNWdwbzRvZThLaEFjcWF4cmQ4cl9INGdiWFhWRVZR?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tonix-pharmaceuticals-attend-btig-infectious-110000093.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T11:00:00+00:00", "published_display": "11 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals director Stillwell buys $58,250 in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOb1FYYzJZM0Q5SEFXX2dFZFo2NnBtZ29wNFMwWC15Q2VvczFYV25TYzVvUjVIbTBKWGgyUkhUQzJfS2ZNcG9TNjVrZkY2QU5GUVpEXzJoTlUwckwxR2NsUDRUS0tqWExmcEJsSlYxWXFIZG5sUVZRbUJ4a1FncTRwSGdsejg2UDFLUTRkM01wQUt5LThUNEpabzdaT0xGdWFlLUt0bm1uZmxhSVRTNFh3Y0Z1YzFPWElXbFdIVXdVMEZxTHM4?oc=5", "source_name": "Investing.com", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fibromyalgia and Lyme biotech Tonix lines up two May investor talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNMzZyYi1URTJSd2hiZUVUdXRYVGIwczh5SGVPd2VDTk5pR2NYazBKei03aHZXeGp2MS04ZFQyOGlGOEhBRzJVdTAweW5hUlBIT0c2RWN5MGhjbHg0dVZvN2xKNXpGQ2ZHYlVSemM3YkRlRkJVLWh5TDZ5b0RibEFwUHMwc0trTFFWSUFQQ0VQVTBoMVJGcEZtNW9yb3U2b25ERlFnbGU1VE56MmJ3aDRjWDBjSVZPMG5hZ250MFlQWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Holding (TNXP) Q1 Loss Deepens To US$40.2 Million Reinforcing Bearish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tonix Pharmaceuticals (NASDAQ: TNXP) shareholders back reverse split authority and new 2026 stock incentive plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZWlGdTlMRThzb1pvZC1PYXdLenFjdU9xRUJfdGhpN3hiZUZFY2ZoVFk3bF9DelEtcktjUmN2Q3U3UGo0VWYwYXM2bkkzMWhVRmdtYUhhYWtrQlUtSmx3aExzalpLcTAyZXUwc3phcHFXWjlUQnptdjlab0l5T2V5bkZnaWROM29QUXFmcEIyRFZob2VwaV9rYU9fYU9jSHdZUGlYQTJCck9INnhMd25yNUdTQkxuMkwtYTRPOFc0WWk?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "35 million insured Americans gain access to Tonix fibromyalgia drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPSlh3QU9PRnF6SzBYbWV5ZEhnbkRDODdfQlFDYm1IMUdNRlZycUpfNFJaY01mSWdSRHhtQnBOLWs4NWpjYllLN0Q4NmgyZHlQNmdQN3FVNXdISXRPT2FMR28zWWhmdG9pMjI0YWptWUlzcjNJMWxCME9ySmZhbjdBckNZdUh3MDl0MVRybW52Qmg5RDhlWWRZME5wR1YtYnY0VFVtakltbnRqVHlNTVFNeWhJcTgzQ1poaUtOSWlR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals (TNXP) Proxy filing Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5YQmlsb0RuQXhnbi1JdmdHNGRKUWpicjFneWdpS1J3ZDVoOHB0RHAzcWMtMDlqS3FWdDgxYVJ5ZTRoNFdPbi1ycWRtbkVEZ1FpdndYVFpJS0FLcEJQNTZ6Wjg3NDNCTlhYOEhiOHJNVFZDaU16bkJWRWxrNG9BbU0?oc=5", "source_name": "Quartr", "published_at": "2026-04-29T23:07:31+00:00", "published_display": "29 Apr 2026 23:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "No U.S. Lyme preventive exists; Tonix tests 4-month single dose", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNdTJoUG1qOWFuMWpSM3FydzZwNGNOY3R0cnN4MFdRenVjaUVPRlpIbzIyT1JqWTdYcWpxM2c0N0xCVkdZR3AxSFRvb2dWUE1wUzJrQXg0ZFNoU014SUVPXzVVQ2lHMkplb25UVTd0d3JuWXR4S2xPZXd0WmptLXVTSEVfdjRBLThuZ25XbE1zeWQwZWV0Uno5ekEtUmlPdUo1V2NfZVNBdkpHRTVXU1dzMjJRb2wyZHpzOG1n?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals (NASDAQ: TNXP) puts reverse split and 2026 equity plan to vote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQYjRjam42RkluaTFpWlU4WUIzYnE0NDJhQk5PeFVsdVZnQ2E2MDRCV0piR3ZDYW9DN0toZzA3QVBTVklTQWVyeWZNbXZHdDUzOHp1VW1rXy1ZUUxoRVBLbGpmYVR4aXRmT20zWWJLUS00Mm10MjBwMmFrREJvUlp0SFNub21lRVJ1ak1qYzI0N3YxajdKbTdZWHRPWU5DWGlUU1h4eUJ5ZFVtY2M1R1ZZTHNteG5qSU4wVkNFc1pkM1BNQ0xvSGJmNlZLbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lyme disease and mpox studies put Tonix on vaccine congress agenda", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZ2Y5MUNOaHM0Mno5b1hzZlZtWUdRbno5Ykw5MFF6SjRpemxuYWpHZGdEOVNCelN0bFZOMFdnT0RHbVBmaVI3RzJSc2lUMmR2c0JoM3I1MEEwMTJEZW5QbV9rYkh2MDBJOTVjYUNlTzJYeHJEaHVMT2pYalU5eDhwSDN5bVdKZ09GMV95bV9lLU5rbkUzMFY0a1JsSVJXY2IxdmVhX1RKMHFZajA5eHpFTHZ3QTd3MGhp?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Auditor change at Tonix (NASDAQ: TNXP) after going concern warning", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNNllVem5hbTE0QjBhWDFtOEo4V09QUnVLam8tVFNiTkpUam1pbWd1Ql9nX0FMcldTVnJGM1V3Qk1TQ0dMUTAtdUlvOVNGaUhUUUxlY0VEcWltbTN1Y3gtZkVtcG9iTGkxa0doanV2RS03a19uMlUyY0x2UUUzekVVR1VHUGhUX0ZwVVpZc05lQzFhd2NpRUNQQ3FjaFFJRGt1U2szNlNxVjg4SVhrVHE5U2JIcWhSOGpvRzlQX08xYTc?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-01T08:00:00+00:00", "published_display": "01 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost \u2014 Traders See \u2018Blueprint For Rerating\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPVmpLUHNXTXlxdkU0SWZ5VVV1T2JOVUpTODkzeWQ1aUpFYWpoaEx3OEUxZGEtVHpYbGoyUGRsOW5uZWx4TklFcWhEakRkY0pzQk9BU2NYem83SnFKTEJGaE5Hcmd0ZzJSdXljUFFqTW9pSWNQU0tpT3c2RTRldGIyRUwxWXgtUXRDU3Y3U1ZON2dGU1FTTkpkUjRmd2ZhYVp2R1Z6X2s1YXRYQlNqRm9QLVNjZVVtMkc1ZFY4WS14eU52U2hNcmplVW5vTy12cjN0R1BsR2ZlNzVuWDZl?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA\u2122 (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPQ0wwcFBqSml2NnJpbUZoWWs2SElpT1dBai1TRG1LZVhoMTZ4bVhLVlpjTDVhcDExeUVtbmVSYllsZktDNm9Lb3BPalg1bmxVZlZIc1ZqU2lKQ3JRcG5CcEJEYWlfeXVHUzZYWjBYemkwZzZQNktXQ0IxZjAzSmlyREx5cDJIaGZBbGZ5c3ZIZnRCZERo?oc=5", "source_name": "Market source", "published_at": "2025-11-17T08:00:00+00:00", "published_display": "17 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail\u2019s Optimistic", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQLS1hanYxVFBPNXVpWlpfZHBZTE44YjVFQVhJLVZQelJxZnl4cVNrRDFuZVJUMHNPZ3Jra01sM0h6VVp5ZkZuTTBiOHNjdzFOOWZMTnNUejdGc2h6cFFSQzhKZ3pOWjRSSUM2R3JhSzZPVWVldmxOMEREaVg5Uk5IMVNocHdVNDZDbFp3THU2N01mWTJGUE5oRFNxTG10alQ3S0p4YlhUWXhRNUY2Z0NVbDM5QURHeE5GVEVqVF9IMnVFLVVGd3ZNLWM4QXItdEljeFFKcGJ5Z1NScVpadDZJ?oc=5", "source_name": "Stocktwits", "published_at": "2025-08-13T01:31:02+00:00", "published_display": "13 Aug 2025 01:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Total debt per share of Tonix Pharmaceuticals Holding Corp. \u2013 GETTEX:TPM0", "summary": "The article focuses on the \"Total debt per share\" of Tonix Pharmaceuticals Holding Corp. (GETTEX:TPM0) as listed on TradingView. It appears to be a financial data page rather than a detailed news article. The content provides navigational links and information about TradingView's", "url": "https://www.tradingview.com/symbols/GETTEX-TPM0/financials-statistics-and-ratios/total-debt-per-share/", "source_name": "TradingView", "published_at": "2026-07-21T04:10:42", "published_display": "21 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals (TNXP) Investor presentation Summary", "summary": "Tonix Pharmaceuticals has launched Tonmya, a sublingual tablet for fibromyalgia, which has achieved $5.1 million in net sales and secured broad commercial and government insurance coverage. The company has a strong cash position of $185.5 million and an extensive pipeline of drug", "url": "https://quartr.com/events/tonix-pharmaceuticals-holding-corp-tnxp-investor-presentation_FPasHadc", "source_name": "Quartr", "published_at": "2026-07-18T01:11:21", "published_display": "18 Jul 2026 01:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models", "summary": "Tonix Pharmaceuticals announced the publication of a study in the Journal of Virology that assesses the virulence of the 2022 mpox outbreak strain (clade IIb) compared to the 2003 strain (clade IIa) using new murine models. The research found that the clade IIb strain is 100 to 1", "url": "https://finance.yahoo.com/healthcare/articles/tonix-pharmaceuticals-announces-publication-peer-130500762.html", "source_name": "Market source", "published_at": "2026-07-16T01:11:22", "published_display": "16 Jul 2026 01:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Paper Introduces Three New Mouse Models for Mpox Vaccine Research", "summary": "Tonix Pharmaceuticals announced that the Journal of Virology published its research on new mpox animal models, revealing that the 2022 clade IIb strain is 100 to 100,000-fold less virulent than the 2003 clade IIa strain. The study expands existing mouse models and introduces thre", "url": "https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-publication-in-the-peer-reviewed-qgbzdklcjmm8.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:46:59", "published_display": "15 Jul 2026 12:46", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Tonix Pharmaceuticals Holding Corp. (TNXP) Risk Zones", "summary": "This article analyzes Tonix Pharmaceuticals Holding Corp. (TNXP), highlighting a mid-channel oscillation pattern and a weak long-term outlook despite positive sentiment. It details distinct AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with specifi", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Tonix_Pharmaceuticals_Holding_Corp._TNXP_Risk_Zones_071426123801_1784003881.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-14T23:46:59", "published_display": "14 Jul 2026 23:46", "sentiment": "negative", "sentiment_pct": 30, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Announces Major Medicare Coverage Agreement for TONMYA, Expanding U.S. Access to Approximately 145 Million Covered Lives", "summary": "Tonix Pharmaceuticals announced a major managed Medicare agreement for TONMYA, adding approximately 9 million Medicare lives starting January 1, 2027, and bringing total covered lives to 145 million. The company is also expanding its sales force by 50 representatives to enhance a", "url": "https://www.quiverquant.com/news/Tonix+Pharmaceuticals+Announces+Major+Medicare+Coverage+Agreement+for+TONMYA,+Expanding+U.S.+Access+to+Approximately+145+Million+Covered+Lives", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T11:13:00", "published_display": "14 Jul 2026 11:13", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP)", "summary": "", "url": "https://finance.yahoo.com/m/b981db40-07b6-31b0-9d13-ad50a7f14be4/tonix-expands-tonmya-medicare.html", "source_name": "InvestorsHub", "published_at": "2026-07-13T12:21:44+00:00", "published_display": "13 Jul 2026 12:21", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tonix-pharmaceuticals-reaches-medicare-coverage-120031738.html", "source_name": "MT Newswires", "published_at": "2026-07-13T12:00:31+00:00", "published_display": "13 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA\u00ae", "summary": "Tonix Pharmaceuticals announced a new agreement for TONMYA (cyclobenzaprine HCl sublingual tablets) with a major managed Medicare payer, effective January 1, 2027, adding approximately 9 million Medicare lives. This expands TONMYA's coverage to about 46% of all covered lives in t", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326064/0/en/Tonix-Pharmaceuticals-Announces-Major-Managed-Medicare-Payer-Agreement-for-TONMYA.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T11:40:06", "published_display": "13 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Adds Medicare Part D Coverage for TONMYA, Expands Sales Force", "summary": "Tonix Pharmaceuticals announced a PBM agreement to secure Medicare Part D coverage for TONMYA, effective January 1, 2027, significantly expanding patient access to approximately 9 million beneficiaries. This new coverage, combined with existing Medicaid and commercial agreements,", "url": "https://www.tradingview.com/news/tradingview:3021d492c14dc:0", "source_name": "TradingView", "published_at": "2026-07-13T11:11:22", "published_display": "13 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals (NASDAQ: TNXP) secures PBM Medicare pact, targeting 145M TONMYA covered lives", "summary": "Tonix Pharmaceuticals has secured an agreement with a pharmacy benefit manager for TONMYA coverage for Medicare Part D beneficiaries, effective January 1, 2027, adding approximately 9 million Medicare lives. This new agreement, combined with existing commercial and Medicaid cover", "url": "https://www.stocktitan.net/sec-filings/TNXP/8-k-tonix-pharmaceuticals-holding-corp-reports-material-event-ad2ff3f89944.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:11:22", "published_display": "13 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fibromyalgia drug TONMYA to reach 145M covered lives by 2027", "summary": "Tonix Pharmaceuticals announced a major managed Medicare agreement for its fibromyalgia drug, TONMYA, adding approximately 9 million Medicare lives, bringing the total projected pharmacy coverage to 145 million covered lives by January 1, 2027. This expansion, combined with exist", "url": "https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-major-managed-medicare-payer-2zlnl3uf4paw.html", "source_name": "Stock Titan", "published_at": "2026-07-13T10:59:33", "published_display": "13 Jul 2026 10:59", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Tonix Pharmaceuticals Holding Corp For: 9 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Tonix Pharmaceuticals Holding Corp. on July 9, 2026. The brief entry provides the company's stock symbol (TNXP) and notes a 1.96% increase, indicating recent activity in the company's stock.", "url": "https://ng.investing.com/news/stock-market-news/form-4-tonix-pharmaceuticals-holding-corp-for-9-july-93CH-2593304", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T14:41:24", "published_display": "09 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix (NASDAQ: TNXP) CFO adds 1,453 shares through 2025 employee stock plan", "summary": "Tonix Pharmaceuticals Holding Corp.'s CFO, Bradley Saenger, acquired 1,453 shares of common stock at $10.914 per share through the company's 2025 Employee Stock Purchase Plan. This transaction, coded as \"J\" for \"other acquisition or disposition,\" is compensation-related and not a", "url": "https://www.stocktitan.net/sec-filings/TNXP/form-4-tonix-pharmaceuticals-holding-corp-insider-trading-activity-05e9cbc53d03.html", "source_name": "Stock Titan", "published_at": "2026-07-09T12:51:43", "published_display": "09 Jul 2026 12:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to TNXP Trends in Macro Strategies", "summary": "The article provides a technical analysis of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) with insights into near, mid-term, and long-term trends. It highlights a strong sentiment in the near and mid-term, but a weak long-term outlook, identifying an exceptional risk-reward", "url": "https://news.stocktradersdaily.com/news_release/35/Technical_Reactions_to_TNXP_Trends_in_Macro_Strategies_070226113001_1783049401.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T23:30:00", "published_display": "02 Jul 2026 23:30", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Announces First Patient Enrolled in", "summary": "Tonix Pharmaceuticals announced the enrollment of the first patient in its Phase 2 HORIZON study for TNX-102 SL, a treatment for Major Depressive Disorder (MDD). The study evaluates TNX-102 SL 5.6 mg as a first-line monotherapy, targeting disturbed sleep quality in MDD patients. ", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318861/0/en/tonix-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-horizon-study-of-tnx-102-sl-for-the-treatment-of-major-depressive-disorder-mdd.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T20:40:44", "published_display": "29 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 \u201cHORIZON\u201d study of TNX-102 SL (sublingual tablet) for the treatment of major depressive disorder (MDD).", "summary": "Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 \"HORIZON\" study for TNX-102 SL, a sublingual tablet designed to treat major depressive disorder (MDD). This milestone, reported to the SEC, marks significant progress in the clinical development of ", "url": "https://www.bitget.com/amp/news/detail/12560605481850", "source_name": "Bitget", "published_at": "2026-06-29T20:11:43", "published_display": "29 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals (TNXP) enrolls first patient in Phase 2 HORIZON MDD trial", "summary": "Tonix Pharmaceuticals has announced the enrollment of the first patient in its Phase 2 HORIZON trial for TNX-102 SL 5.6 mg as a first-line monotherapy for adults with major depressive disorder (MDD). This 6-week, randomized, double-blind, placebo-controlled study plans to enroll ", "url": "https://www.stocktitan.net/sec-filings/TNXP/8-k-tonix-pharmaceuticals-holding-corp-reports-material-event-121c965a72d3.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:10:33", "published_display": "29 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix enrolls first patient in Phase 2 depression study", "summary": "Tonix Pharmaceuticals has enrolled the first patient in its Phase 2 HORIZON study for major depressive disorder. The trial will involve approximately 360 patients across 30 U.S. sites and will assess TNX-102 SL (TONMYA), which is already FDA-approved for fibromyalgia, as a first-", "url": "https://grafa.com/en/news/united-states/tonix-horizon-depression-phase2-first-patient", "source_name": "grafa.com", "published_at": "2026-06-29T16:03:00", "published_display": "29 Jun 2026 16:03", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tonix-pharmaceuticals-advances-tnx-102-121519915.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:15:19+00:00", "published_display": "29 Jun 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for Major Depressive Disorder", "summary": "Tonix Pharmaceuticals has announced the enrollment of the first patient in its Phase 2 HORIZON study for TNX-102 SL, investigating its use as a first-line treatment for major depressive disorder (MDD). The study aims to enroll approximately 360 participants to evaluate changes in", "url": "https://www.quiverquant.com/news/Tonix+Pharmaceuticals+Announces+First+Patient+Enrolled+in+Phase+2+HORIZON+Study+of+TNX-102+SL+for+Major+Depressive+Disorder", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T11:30:00", "published_display": "29 Jun 2026 11:30", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)", "summary": "Tonix Pharmaceuticals has enrolled the first patient in its Phase 2 HORIZON study for TNX-102 SL in treating major depressive disorder (MDD). The 6-week, randomized, double-blind, placebo-controlled trial aims to enroll approximately 360 adults and will evaluate the drug as a fir", "url": "https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-fmo8cidv858m.html", "source_name": "Stock Titan", "published_at": "2026-06-29T11:11:57", "published_display": "29 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating (NASDAQ:TNXP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNV2RRcGpfOGRCZnFOLWRzSHVEQW8ySzU3QjQwZ096bm9iZUFXZEJVRF94RGdQYktNYUo0ZUpvLTJ4V0hyR0xxNm5tRWExR1dUTGNPaWlsN0p5Wk9KNU44TkFsOFBDa3YyZEVPb1drTUY4Z19hQ1dGV0ZTZjVwZEJMUklIdE5tOHdJUGV1Z25aY3VjcWoyamllb2hhV3QwbmZmbmlIVmlqT3hhbzBmaUdv?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/raymond-james-initiates-coverage-tonix-113700673.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:37:00+00:00", "published_display": "25 Jun 2026 11:37", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium group reports 890,366 shares (5.6%) in Tonix (TNXP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQZnRYM1J2R0l3aUpoQVlScVhXX0JPTHJfWDdwUC05TU1LbFhzS2pmLXJYOUM0RHpISkNrZzhwZFdLVHktaUo2VXdWbDB6U1prMXFhMjJpREdoeXcwbVpMay1iSVllVnpoRjJNQ3cxNENlcG1FR25SeGpTdkxEX2haV0R3ZUxEM0FhdXZicC12VHNxNnZJTzlWa1BZSDJ2WG1FM3JicGItZ1RSQlpocnhHdlI2QzRlX0ZTdTlaX0pRSHpMUjk5TlptdHE3OA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Carolyn Taylor buys Tonix Pharmaceuticals (TNXP) shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPLVBfNDZudGYzWEdHcnF5Qnlna3o3RnlnWlF4X2JnYVFhUWVJbzFkd3Fqc3RldDdnUHZub0ZaaTRPTHUycS0zSENvNEtra19NM1hKaHJDUy0tWjBKVHFTQ3JGQXpQZFNKaFJEdnlGblQzUmo1QkNuV01jT3VCQ19YajF1bnBldU85ZmJ2X1NDcm5PVEhibXRLaEN4RlRsT29wN3E3V25rR2t5RWFnNFFyLWxMZG1feUVObzdfRVpkYlB1bUlmaFJv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOVkRoYUF1U0tkbXEzYzF2VElfLTcweEtWRzZPUGpFbUJiWUhncHRkd3F1bWJPSTFCdG1FSVVzZGh3OUsxX1BkazU0dGRwNVNvaWRiazFHWndwUDRjeDY4N3BhT2FmM3F2VjhFcGI5VF9LMUh3MDJJQmU0a2xST2YtTzdUVXRlOXJXNWdwbzRvZThLaEFjcWF4cmQ4cl9INGdiWFhWRVZR?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tonix-pharmaceuticals-attend-btig-infectious-110000093.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T11:00:00+00:00", "published_display": "11 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals director Stillwell buys $58,250 in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOb1FYYzJZM0Q5SEFXX2dFZFo2NnBtZ29wNFMwWC15Q2VvczFYV25TYzVvUjVIbTBKWGgyUkhUQzJfS2ZNcG9TNjVrZkY2QU5GUVpEXzJoTlUwckwxR2NsUDRUS0tqWExmcEJsSlYxWXFIZG5sUVZRbUJ4a1FncTRwSGdsejg2UDFLUTRkM01wQUt5LThUNEpabzdaT0xGdWFlLUt0bm1uZmxhSVRTNFh3Y0Z1YzFPWElXbFdIVXdVMEZxTHM4?oc=5", "source_name": "Investing.com", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fibromyalgia and Lyme biotech Tonix lines up two May investor talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNMzZyYi1URTJSd2hiZUVUdXRYVGIwczh5SGVPd2VDTk5pR2NYazBKei03aHZXeGp2MS04ZFQyOGlGOEhBRzJVdTAweW5hUlBIT0c2RWN5MGhjbHg0dVZvN2xKNXpGQ2ZHYlVSemM3YkRlRkJVLWh5TDZ5b0RibEFwUHMwc0trTFFWSUFQQ0VQVTBoMVJGcEZtNW9yb3U2b25ERlFnbGU1VE56MmJ3aDRjWDBjSVZPMG5hZ250MFlQWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Holding (TNXP) Q1 Loss Deepens To US$40.2 Million Reinforcing Bearish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals (NASDAQ: TNXP) shareholders back reverse split authority and new 2026 stock incentive plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZWlGdTlMRThzb1pvZC1PYXdLenFjdU9xRUJfdGhpN3hiZUZFY2ZoVFk3bF9DelEtcktjUmN2Q3U3UGo0VWYwYXM2bkkzMWhVRmdtYUhhYWtrQlUtSmx3aExzalpLcTAyZXUwc3phcHFXWjlUQnptdjlab0l5T2V5bkZnaWROM29QUXFmcEIyRFZob2VwaV9rYU9fYU9jSHdZUGlYQTJCck9INnhMd25yNUdTQkxuMkwtYTRPOFc0WWk?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "35 million insured Americans gain access to Tonix fibromyalgia drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPSlh3QU9PRnF6SzBYbWV5ZEhnbkRDODdfQlFDYm1IMUdNRlZycUpfNFJaY01mSWdSRHhtQnBOLWs4NWpjYllLN0Q4NmgyZHlQNmdQN3FVNXdISXRPT2FMR28zWWhmdG9pMjI0YWptWUlzcjNJMWxCME9ySmZhbjdBckNZdUh3MDl0MVRybW52Qmg5RDhlWWRZME5wR1YtYnY0VFVtakltbnRqVHlNTVFNeWhJcTgzQ1poaUtOSWlR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals (TNXP) Proxy filing Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5YQmlsb0RuQXhnbi1JdmdHNGRKUWpicjFneWdpS1J3ZDVoOHB0RHAzcWMtMDlqS3FWdDgxYVJ5ZTRoNFdPbi1ycWRtbkVEZ1FpdndYVFpJS0FLcEJQNTZ6Wjg3NDNCTlhYOEhiOHJNVFZDaU16bkJWRWxrNG9BbU0?oc=5", "source_name": "Quartr", "published_at": "2026-04-29T23:07:31+00:00", "published_display": "29 Apr 2026 23:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "No U.S. Lyme preventive exists; Tonix tests 4-month single dose", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNdTJoUG1qOWFuMWpSM3FydzZwNGNOY3R0cnN4MFdRenVjaUVPRlpIbzIyT1JqWTdYcWpxM2c0N0xCVkdZR3AxSFRvb2dWUE1wUzJrQXg0ZFNoU014SUVPXzVVQ2lHMkplb25UVTd0d3JuWXR4S2xPZXd0WmptLXVTSEVfdjRBLThuZ25XbE1zeWQwZWV0Uno5ekEtUmlPdUo1V2NfZVNBdkpHRTVXU1dzMjJRb2wyZHpzOG1n?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals (NASDAQ: TNXP) puts reverse split and 2026 equity plan to vote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQYjRjam42RkluaTFpWlU4WUIzYnE0NDJhQk5PeFVsdVZnQ2E2MDRCV0piR3ZDYW9DN0toZzA3QVBTVklTQWVyeWZNbXZHdDUzOHp1VW1rXy1ZUUxoRVBLbGpmYVR4aXRmT20zWWJLUS00Mm10MjBwMmFrREJvUlp0SFNub21lRVJ1ak1qYzI0N3YxajdKbTdZWHRPWU5DWGlUU1h4eUJ5ZFVtY2M1R1ZZTHNteG5qSU4wVkNFc1pkM1BNQ0xvSGJmNlZLbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyme disease and mpox studies put Tonix on vaccine congress agenda", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZ2Y5MUNOaHM0Mno5b1hzZlZtWUdRbno5Ykw5MFF6SjRpemxuYWpHZGdEOVNCelN0bFZOMFdnT0RHbVBmaVI3RzJSc2lUMmR2c0JoM3I1MEEwMTJEZW5QbV9rYkh2MDBJOTVjYUNlTzJYeHJEaHVMT2pYalU5eDhwSDN5bVdKZ09GMV95bV9lLU5rbkUzMFY0a1JsSVJXY2IxdmVhX1RKMHFZajA5eHpFTHZ3QTd3MGhp?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Auditor change at Tonix (NASDAQ: TNXP) after going concern warning", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNNllVem5hbTE0QjBhWDFtOEo4V09QUnVLam8tVFNiTkpUam1pbWd1Ql9nX0FMcldTVnJGM1V3Qk1TQ0dMUTAtdUlvOVNGaUhUUUxlY0VEcWltbTN1Y3gtZkVtcG9iTGkxa0doanV2RS03a19uMlUyY0x2UUUzekVVR1VHUGhUX0ZwVVpZc05lQzFhd2NpRUNQQ3FjaFFJRGt1U2szNlNxVjg4SVhrVHE5U2JIcWhSOGpvRzlQX08xYTc?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-01T08:00:00+00:00", "published_display": "01 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost \u2014 Traders See \u2018Blueprint For Rerating\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPVmpLUHNXTXlxdkU0SWZ5VVV1T2JOVUpTODkzeWQ1aUpFYWpoaEx3OEUxZGEtVHpYbGoyUGRsOW5uZWx4TklFcWhEakRkY0pzQk9BU2NYem83SnFKTEJGaE5Hcmd0ZzJSdXljUFFqTW9pSWNQU0tpT3c2RTRldGIyRUwxWXgtUXRDU3Y3U1ZON2dGU1FTTkpkUjRmd2ZhYVp2R1Z6X2s1YXRYQlNqRm9QLVNjZVVtMkc1ZFY4WS14eU52U2hNcmplVW5vTy12cjN0R1BsR2ZlNzVuWDZl?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA\u2122 (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPQ0wwcFBqSml2NnJpbUZoWWs2SElpT1dBai1TRG1LZVhoMTZ4bVhLVlpjTDVhcDExeUVtbmVSYllsZktDNm9Lb3BPalg1bmxVZlZIc1ZqU2lKQ3JRcG5CcEJEYWlfeXVHUzZYWjBYemkwZzZQNktXQ0IxZjAzSmlyREx5cDJIaGZBbGZ5c3ZIZnRCZERo?oc=5", "source_name": "Market source", "published_at": "2025-11-17T08:00:00+00:00", "published_display": "17 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail\u2019s Optimistic", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQLS1hanYxVFBPNXVpWlpfZHBZTE44YjVFQVhJLVZQelJxZnl4cVNrRDFuZVJUMHNPZ3Jra01sM0h6VVp5ZkZuTTBiOHNjdzFOOWZMTnNUejdGc2h6cFFSQzhKZ3pOWjRSSUM2R3JhSzZPVWVldmxOMEREaVg5Uk5IMVNocHdVNDZDbFp3THU2N01mWTJGUE5oRFNxTG10alQ3S0p4YlhUWXhRNUY2Z0NVbDM5QURHeE5GVEVqVF9IMnVFLVVGd3ZNLWM4QXItdEljeFFKcGJ5Z1NScVpadDZJ?oc=5", "source_name": "Stocktwits", "published_at": "2025-08-13T01:31:02+00:00", "published_display": "13 Aug 2025 01:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 51, "sentiment_summary": {"positive": 17, "negative": 5, "neutral": 29, "score": 57, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 15.95, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 3.71, "count": 9}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 1.45, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}], "positive_events": 17, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 12.43, "latest_week": "2026-07-17", "one_week_move": -0.8, "four_week_move": 3.5, "twelve_week_move": -1.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.405676, "market_dynamics_buy_signal": false, "relative_strength": -43.611668, "fair_value_gap": -97.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.9343, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.8% over one week, +3.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 15}, {"label": "Market source", "count": 9}, {"label": "simplywall.st", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Quartr", "count": 2}, {"label": "Stock Traders Daily", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 9}, {"label": "Balance sheet", "count": 5}, {"label": "Guidance", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.8% over one week, +3.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Total debt per share of Tonix Pharmaceuticals Holding Corp. \u2013 GETTEX:TPM0"}], "updated_at": "2026-07-22T13:37:01.812200+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}